These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7564077)

  • 1. Lipid-lowering therapy in patients with renal disease.
    Massy ZA; Ma JZ; Louis TA; Kasiske BL
    Kidney Int; 1995 Jul; 48(1):188-98. PubMed ID: 7564077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
    Olyaei A; Greer E; Delos Santos R; Rueda J
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
    Farnier M
    Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of change of renal replacement therapy on serum lipoprotein (a) concentration.
    Misra M; Webb AT; Reaveley DA; Doherty E; O'Donnell M; Seed M; Brown EA
    Adv Perit Dial; 1997; 13():168-73. PubMed ID: 9360675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients?
    Nauck M; Krämer-Guth A; Bartens W; März W; Wieland H; Wanner C
    Clin Nephrol; 1996 Nov; 46(5):319-25. PubMed ID: 8953121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
    Harris KP; Wheeler DC; Chong CC;
    Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
    Saltissi D; Westhuyzen J; Morgan C; Healy H
    Clin Exp Nephrol; 2006 Sep; 10(3):201-9. PubMed ID: 17009078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
    Wheeler DC
    J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hyperlipidemia in human renal disease.
    D'Amico GD; Gentile MG
    Miner Electrolyte Metab; 1993; 19(3):196-204. PubMed ID: 8232107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy?
    Kronenberg F; Lingenhel A; Lhotta K; Rantner B; Kronenberg MF; König P; Thiery J; Koch M; von Eckardstein A; Dieplinger H
    Kidney Int; 2004 Jul; 66(1):348-54. PubMed ID: 15200443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients.
    Kronenberg F; Lingenhel A; Neyer U; Lhotta K; König P; Auinger M; Wiesholzer M; Andersson H; Dieplinger H
    Kidney Int Suppl; 2003 May; (84):S113-6. PubMed ID: 12694323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
    Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
    Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins and renal diseases: from primary prevention to renal replacement therapy.
    D'Amico G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S148-52. PubMed ID: 16565241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ezetimibe and low-dose simvastatin as primary treatment for dyslipidemia in peritoneal dialysis patients.
    Suzuki H; Inoue T; Watanabe Y; Kikuta T; Sato T; Tsuda M
    Adv Perit Dial; 2010; 26():53-7. PubMed ID: 21348380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of lipid-lowering agents on acute renal allograft rejection.
    Kasiske BL; Heim-Duthoy KL; Singer GG; Watschinger B; Germain MJ; Bastani B
    Transplantation; 2001 Jul; 72(2):223-7. PubMed ID: 11477342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can group medical clinics improve lipid management in diabetes?
    Crowley MJ; Melnyk SD; Ostroff JL; Fredrickson SK; Jeffreys AS; Coffman CJ; Edelman D
    Am J Med; 2014 Feb; 127(2):145-51. PubMed ID: 24462012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.